Immunexpress is providing an update on Septicyte Rapid commercialization plans (See below).
FL
Immunexpress CEO To Present at the Virtual Biotech Showcase 2022
SEATTLE, Jan. 4, 2022 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today that Chief Executive Officer, Rolland Carlson, Ph.D., to present a corporate update, accessible on demand, at the virtual Biotech Showcase 2022 to be held Jan. 10-12 and Jan. 17–19, 2022.
Dr. Carlson will present an overview of Immunexpress' SeptiCyte® technology and a corporate update on commercial plans for newly FDA cleared sepsis diagnostic SeptiCyte® RAPID. Dr. Carlson is available for virtual meetings.